Search - tctmd.com

Displaying 1 - 6 of 6

Sort: Relevancy | Date

LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Presentation TCT 2019

LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease

Presenter: Kenneth Ouriel

September 28, 2019

Extended Follow-up From LEVANT 2: Two-Year Follow-up and Subgroup Analyses

Presentation TCT 2015

Extended Follow-up From LEVANT 2: Two-Year Follow-up and Subgroup Analyses

Presenter: William A. Gray, Peter A. Schneider, Andrej Schmidt

October 12, 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Randomized Controlled Trials I: Extended Follow-Up From LEVANT 2 - Analysis of one year Follow-up and Beyond

Presentation TCT 2014

Randomized Controlled Trials I: Extended Follow-Up From LEVANT 2 - Analysis of one year Follow-up and Beyond

Presenter: Kenneth Rosenfield, Thomas Zeller, Raghu Kolluri

September 15, 2014

Presentation TCT 2013

LEVANT 2

Presenter: D. Christopher Metzger

October 31, 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presentation TCT 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presenter: Kenneth Rosenfield

October 30, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.